Premium
P4–001: Soluble amyloid–beta leads to mitochondrial failure in APP and tau transgenic mice
Author(s) -
Eckert Anne,
Hauptmann Susanne,
Scherping Isabel,
Bonert Astrid,
Müller-Spahn Franz,
Götz Jürgen,
Müller Walter E.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1739
Subject(s) - genetically modified mouse , endocrinology , beta (programming language) , mitochondrion , medicine , amyloid precursor protein , amyloid beta , cytochrome c oxidase , oxidative stress , transgene , amyloid (mycology) , biology , chemistry , alzheimer's disease , microbiology and biotechnology , pathology , biochemistry , disease , gene , computer science , programming language
Background: Cholinesterase inhibitors, which are now the recommended treatment for patients with mild to moderate Alzheimer’s Disease have been in use since the late 1990’s. Most clinical drug trials using these drugs are short term with some long-term open-label extensions. Few long-term studies are done in clinical practice settings where patients may differ in clinical profile and ethnicity from those enrolled in clinical trials. Objective: This study aims to evaluate the efficacy of a cholinesterase inhibitor, donepezil, in patients with probable mild to moderate Alzheimer’s Disease in a clinical practice setting over a period of two years in an Asian population. Methods: This study was conducted in patients with Alzheimer’s Disease who were evaluated and treated at the St. Luke’s Memory Center in the Philippines. Thirty-nine patients were treated with Donepezil in accordance with approved product information (up to 10 mg/day). The medication was given open-label while independent raters blinded to treatment administered the cognitive tests. A responsible family caregiver for every patient was available to ensure compliance with the medications. Follow-up period was two years. Results: The mean age was 75.15 7.06, 82.1% were women, and 87.2% had mild dementia. The baseline Mini Mental State Examination (MMSE) was 19.41 4.91. Improvement from baseline MMSE was observed at 6 months (mean change of 2.04 points) and was sustained up to 12 months. Following this, decline below baseline assessments was observed at 1.5 years and with mean decline -0.63 at 2 years. Conclusion: This study showed that treatment with Donepezil delays cognitive decline up to one year and stabilizes cognitive function over a period of two years. The decline after 1 year is slower and later than expected of patients left untreated. The results are also consistent with findings reported in other ethnic populations.